BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · $80,000.00 income · posted Jul 18, 2025

Lobbying activity 2

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement

Tariff (miscellaneous tariff bills)

Reciprocal Tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.